Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 17/20 | 0.55 |
| ▸ | JAK2 | O60674 | 13/20 | 0.54 |
| ▸ | TYK2 | P29597 | 6/20 | 0.48 |
| ▸ | JAK3 | P52333 | 6/20 | 0.48 |
| ▸ | STAT3 | P40763 | 3/20 | 0.48 |
| ▸ | KDR | P35968 | 3/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.48 |
| ▸ | ABL1 | P00519 | 2/20 | 0.48 |
| ▸ | GSK3B | P49841 | 2/20 | 0.48 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15056030 | 1.00 | JAK1 (0.55) | JAK1JAK2TYK2JAK3STAT3 | |
| SCHEMBL15058843 | 0.89 | JAK3 (0.45) | JAK1JAK2JAK3 | |
| SCHEMBL15058844 | 0.89 | JAK3 (0.45) | JAK1JAK2JAK3 | |
| SCHEMBL15056223 | 0.86 | JAK1 (0.54) | JAK1JAK2TYK2JAK3KDR | |
| SCHEMBL15057045 | 0.86 | JAK1 (0.54) | JAK1JAK2TYK2JAK3KDR | |
| SCHEMBL15056225 | 0.86 | JAK1 (0.54) | JAK1JAK2TYK2JAK3KDR | |
| SCHEMBL15058428 | 0.83 | JAK1 (0.66) | JAK1JAK2TYK2JAK3AURKA | |
| SCHEMBL15058427 | 0.83 | JAK1 (0.66) | JAK1JAK2TYK2JAK3AURKA | |
| SCHEMBL15058589 | 0.82 | JAK1 (0.54) | JAK1JAK2TYK2JAK3STAT3 | |
| SCHEMBL15058430 | 0.81 | JAK1 (0.53) | JAK1JAK2TYK2JAK3AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150005281-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS KINASE INHIBITORS | CELLZOME LIMITED (GB) | 2015-01-01 | — | — | US | claimed |
| US-20150005281-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS KINASE INHIBITORS | CELLZOME LIMITED (GB) | 2015-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005281-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS KINASE INHIBITORS | JAK2, JAK1, JAK3 | JAK1 2/4885JAK2 1/4885TYK2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.